Medicine and Dentistry
Chronic Obstructive Pulmonary Disease
89%
Asthma
73%
Disease
31%
Symptom
24%
Emphysema
23%
Quality of Life
16%
Lung Volume
15%
Forced Expiratory Volume
14%
Primary Health Care
13%
Randomized Controlled Trial
13%
Systematic Review
12%
Endobronchial Valve
12%
Drug Therapy
11%
Extracellular Matrix
11%
Childbirth
11%
Airway Obstruction
10%
Cohort Analysis
10%
Neoplasm
9%
Prevalence
9%
Dyspnea
8%
Meta-Analysis
8%
Respiratory Tract Allergy
8%
Health Care Cost
8%
Diagnosis
8%
Smoking
8%
Airway Smooth Muscle
7%
Placebo
7%
Wheeze
7%
Respiratory Tract Inflammation
7%
Silo-Filler's Disease
7%
Non Small Cell Lung Cancer
6%
COVID-19
6%
In Vitro
6%
Mastocytosis
6%
Noninvasive Ventilation
6%
Gene Expression
6%
Cost-Effectiveness Analysis
6%
Bronchodilating Agent
6%
Patient with Asthma
6%
Health Status
6%
Infection
5%
Epithelial Cell
5%
Respiratory Disease
5%
Food Allergy
5%
Lung Transplantation
5%
Odds Ratio
5%
Adverse Event
5%
Airway Smooth Muscle Cell
5%
Body Mass Index
5%
Pulmonary Rehabilitation
5%
St. George Respiratory Questionnaire
5%
Computer Assisted Tomography
5%
Cystic Fibrosis
5%
Spirometry
5%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
100%
Chronic Obstructive Lung Disease
84%
Disease
35%
Symptom
25%
Pharmacokinetics
25%
Cohort Study
16%
Cigarette Smoke
16%
Emphysema
16%
Inflammation
13%
Mouse
13%
Therapeutic Drug Monitoring
12%
Prevalence
12%
Respiratory Tract Allergy
12%
Placebo
12%
Cystic Fibrosis
12%
Randomized Controlled Trial
11%
Allergen
11%
Adverse Event
9%
Respiratory Tract Inflammation
9%
Respiratory Tract Disease
9%
Bronchodilating Agent
8%
Airway Obstruction
8%
Airway Remodeling
8%
Lung Disease
8%
Methacholine
8%
Immunoglobulin E
7%
Non Small Cell Lung Cancer
7%
Infection
7%
Dyspnea
7%
Neoplasm
6%
Tobramycin
6%
Clinical Trial
6%
Allergic Asthma
6%
Receptor
6%
Budesonide
6%
Obesity
6%
Malignant Neoplasm
5%
Immunotherapy
5%
Histamine
5%
Beta 2 Adrenergic Receptor Stimulating Agent
5%
Cytokine
5%
Fluticasone
5%
Biological Marker
5%
Keyphrases
Asthma
44%
Chronic Obstructive Pulmonary Disease
32%
Forced Expiratory Volume in 1 Second (FEV1)
15%
Inhaled Corticosteroids
11%
Lung Function
9%
Pharmacokinetics
8%
Emphysema
7%
COPD Patients
7%
Airway
6%
Lung
6%
Netherlands
6%
Bronchoscopic Lung Volume Reduction
6%
Airway Hyperresponsiveness
5%
Meta-analysis
5%
Cigarette Smoking
5%
Therapeutic Drug Monitoring
5%
Severe Emphysema
5%
Chronic Obstructive Pulmonary Disease Patient
5%
Quality of Life
5%
Dutch
5%
Cystic Fibrosis
5%
Asthma Treatment
5%
Airway Smooth muscle
5%